• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.

作者信息

Gaertner Sébastien, Cordeanu Elena-Mihaela, Mirea Corina, Stephan Dominique

机构信息

Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.

Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.

出版信息

Int J Cardiol. 2015;186:141-2. doi: 10.1016/j.ijcard.2015.03.234. Epub 2015 Mar 18.

DOI:10.1016/j.ijcard.2015.03.234
PMID:25818758
Abstract
摘要

相似文献

1
Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.
Int J Cardiol. 2015;186:141-2. doi: 10.1016/j.ijcard.2015.03.234. Epub 2015 Mar 18.
2
Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.心房颤动与慢性肾脏病：聚焦于利伐沙班
J Comp Eff Res. 2015 Nov;4(6):651-64. doi: 10.2217/cer.15.44. Epub 2015 Sep 21.
3
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].地高辛在心房颤动患者中的应用及不良心血管结局：利伐沙班每日一次口服直接抑制因子Xa与维生素K拮抗剂预防心房颤动患者卒中及栓塞的随机对照试验（ROCKET AF）的回顾性分析
Semergen. 2016 May-Jun;42(4):260-2. doi: 10.1016/j.semerg.2015.08.008. Epub 2015 Dec 1.
4
[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].[非瓣膜性心房颤动患者中直接口服抗凝剂与维生素K拮抗剂相关因素]
Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032. Epub 2015 Jul 29.
5
Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.非维生素K拮抗剂口服抗凝剂用于非瓣膜性心房颤动患者的疗效和安全性比较
Semin Thromb Hemost. 2015 Mar;41(2):146-53. doi: 10.1055/s-0035-1544156. Epub 2015 Feb 15.
6
Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.利伐沙班与维生素K拮抗剂用于房颤消融和复律时的卒中及血栓栓塞风险的荟萃分析。
Int J Cardiol. 2015;187:345-53. doi: 10.1016/j.ijcard.2015.03.323. Epub 2015 Mar 21.
7
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.利伐沙班与心房颤动患者的卒中预防：新证据
Expert Rev Cardiovasc Ther. 2014 Aug;12(8):933-47. doi: 10.1586/14779072.2014.931223. Epub 2014 Jun 19.
8
Direct oral anticoagulants: to switch or not to switch?直接口服抗凝剂：换药还是不换药？
Neth J Med. 2015 Oct;73(8):359-61.
9
Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.接受维生素K拮抗剂治疗的患者发生血栓形成或出血事件的相关危险因素。
J Mal Vasc. 2014 Jul;39(4):248-55. doi: 10.1016/j.jmv.2014.04.002. Epub 2014 Jun 2.
10
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.研究结束时从研究药物转换为开放标签维生素K拮抗剂治疗：ROCKET AF研究经验
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):470-8. doi: 10.1161/CIRCOUTCOMES.113.000132. Epub 2013 Jun 11.